A newly introduced acquisition might have a huge impact on how scientific trials are carried out, significantly in neighborhood oncology settings. Paradigm Well being, a comparatively younger firm based in 2021, is buying Flatiron Well being’s scientific analysis enterprise, which incorporates an in depth tech-enabled U.S. oncology analysis community and a set of scientific analysis options.
Flatiron has constructed up an oncology-focused EHR community and a de-identified database with greater than 4 million affected person information. Greater than 1,000 analysis publications have used its EHR-derived real-world knowledge.
Via this transaction for an undisclosed sum, Paradigm Well being will develop its community to incorporate greater than 25 tutorial medical facilities and well being methods, in addition to entry to almost 100 neighborhood oncology practices nationwide, reaching over 2.4 million sufferers throughout the US.
Paradigm, which was incubated by ARCH Enterprise Companions to deal with inequities in affected person entry to scientific analysis, describes this as an acquisition but in addition as a multi-year collaboration between the 2 organizations to maximise the advantages for suppliers, sponsors, and sufferers. It stated the long-term collaboration will combine Flatiron’s established scientific analysis options and website community with Paradigm Well being’s end-to-end know-how platform, enabling extra sufferers to entry scientific trials, with out including expensive infrastructure.
Paradigm’s AI-enabled infrastructure automates affected person matching and website feasibility, and has helped well being methods accrue to trials 4 occasions quicker whereas decreasing supplier burden and accelerating timelines for biopharma sponsors. Paradigm Well being additionally just lately launched a Trial Design Service to allow sponsors to design and execute interventional and pragmatic trials embedded instantly into routine care.
The 2 organizations will work to combine Paradigm Well being’s options into Flatiron’s OncoEMR and deploy new capabilities. OncoEMR is an digital well being report for neighborhood oncology. Over 4,500 suppliers throughout the Flatiron community of 1,000 community-based most cancers care places use OncoEMR for affected person care and follow operations.
Based in 2012, Flatiron is an unbiased affiliate of the Roche Group. It collaborates with companions in tutorial establishments, coverage teams, regulators, and biopharmaceutical firms. In November 2024, Healthcare Innovation interviewed Neal Meropol, MD, Flatiron’s vice chairman of analysis oncology.
Paradigm Well being will present scientific analysis help to all Flatiron Well being OncoEMR clients and Flatiron’s current scientific analysis associate tutorial medical facilities and well being methods.
“This partnership brings collectively the strengths of each organizations,” stated Nathan Hubbard, Flatiron Well being CEO, in an announcement. “By combining Paradigm Well being’s AI-powered trial infrastructure with Flatiron’s trusted community and help throughout tutorial and neighborhood oncology websites, we’re constructing a stronger, extra related ecosystem for scientific analysis – increasing capabilities, accelerating influence and advancing our shared mission to deliver new remedies to sufferers quicker.”
Paradigm stated the transaction additionally strengthens its relationships with the biopharma trade. The mixed community allows Paradigm Well being to serve 15 of the highest 20 international biopharma firms and provides capability to run pragmatically designed Part IV scientific trials embedded into routine care, rising the pace of post-market approval proof technology.
Paradigm Well being additionally introduced an oversubscribed $78 million Sequence B financing. The spherical was led by ARCH Enterprise Companions, with participation from new investor DFJ Progress and current traders F-Prime, Basic Catalyst, GV, Lux Capital, Mubadala Capital, the American Most cancers Society’s BrightEdge Fund, and others.
